BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic

Reuters03-18

** Shares of drugmaker Lantheus Holdings LNTH.O fall 1.1% to $80.79

** Co on Tuesday said the FDA extended its review of LNTH‑2501, an experimental radioactive diagnostic for cancer, by three months

** Co's LNTH‑2501 is designed to help doctors spot neuroendocrine tumors, a type of cancer that starts in hormone‑producing cells, in adults and children - LNTH

** FDA action pushes the decision date to June 29, 2026, co says

** Co says the delay is linked to extra time needed to review manufacturing information, not the drug’s safety or effectiveness

** LNTH‑2501 is not yet approved and is not available for sale in the U.S. - LNTH

** Shares down ~26% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620025164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620025164","market":"nz","top_or_hot":-1,"title":"BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic</title></head><body><p>** Shares of drugmaker Lantheus Holdings <span>LNTH.O</span> fall 1.1% to $80.79</p><p>** Co on Tuesday said the FDA <span>extended its review</span> of LNTH‑2501, an experimental radioactive diagnostic for cancer, by three months</p><p>** Co's LNTH‑2501 is designed to help doctors spot neuroendocrine tumors, a type of cancer that starts in hormone‑producing cells, in adults and children - LNTH</p><p>** FDA action pushes the decision date to June 29, 2026, co says</p><p>** Co says the delay is linked to extra time needed to review manufacturing information, not the drug’s safety or effectiveness</p><p>** LNTH‑2501 is not yet approved and is not available for sale in the U.S. - LNTH</p><p>** Shares down ~26% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic</title></head><body><p>** Shares of drugmaker Lantheus Holdings <span>LNTH.O</span> fall 1.1% to $80.79</p><p>** Co on Tuesday said the FDA <span>extended its review</span> of LNTH‑2501, an experimental radioactive diagnostic for cancer, by three months</p><p>** Co's LNTH‑2501 is designed to help doctors spot neuroendocrine tumors, a type of cancer that starts in hormone‑producing cells, in adults and children - LNTH</p><p>** FDA action pushes the decision date to June 29, 2026, co says</p><p>** Co says the delay is linked to extra time needed to review manufacturing information, not the drug’s safety or effectiveness</p><p>** LNTH‑2501 is not yet approved and is not available for sale in the U.S. - LNTH</p><p>** Shares down ~26% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL4N4060QE:1","article_id":"2620025164","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620025164","pubTimestamp":1773841237,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic** Shares of drugmaker Lantheus Holdings LNTH.O fall 1.1% to $80.79** Co on Tuesday said the FDA extended its review of LNTH2501, an experimental radioactive diagnostic for cancer, by three months** Co's LNTH2501 is designed to help doctors spot neuroendocrine tumors, a type of cancer that starts in hormoneproducing cells, in adults and children - LNTH** FDA action pushes the decision date to June 29, 2026, co says** Co says the delay is linked to extra time needed to review manufacturing information, not the drug’s safety or effectiveness** LNTH2501 is not yet approved and is not available for sale in the U.S. - LNTH** Shares down ~26% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","LNTH":"Lantheus Holdings, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"FDA延长对实验性癌症诊断的审查，BUZZ-Lantheus股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNTH":0.9},"content_text":"BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic** Shares of drugmaker Lantheus Holdings LNTH.O fall 1.1% to $80.79** Co on Tuesday said the FDA extended its review of LNTH‑2501, an experimental radioactive diagnostic for cancer, by three months** Co's LNTH‑2501 is designed to help doctors spot neuroendocrine tumors, a type of cancer that starts in hormone‑producing cells, in adults and children - LNTH** FDA action pushes the decision date to June 29, 2026, co says** Co says the delay is linked to extra time needed to review manufacturing information, not the drug’s safety or effectiveness** LNTH‑2501 is not yet approved and is not available for sale in the U.S. - LNTH** Shares down ~26% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620025164","isCrawlerRequest":true}